Revolution Medicines reported Phase 3 RASolute 302 results for daraxonrasib, a pan-RAS inhibitor, showing a median overall survival of 13.2 months versus 6.7 months with chemotherapy in 500 previously treated patients with advanced pancreatic ductal adenocarcinoma. The trial also met progression-delay benchmarks, with median time to progression at 7.2 months versus 3.6 months in the chemotherapy arm. The findings, presented at the American Society of Clinical Oncology (ASCO) 2026 and published in the New England Journal of Medicine, target a longstanding challenge: RAS proteins have been difficult drug targets due to limited binding pockets and rapid resistance evolution. Daraxonrasib is designed to shut down all three RAS family members, aiming to broaden activity beyond single-mutation approaches. The program received notable attention from clinicians given the historically limited progress in metastatic pancreatic cancer and the trial’s head-to-head design versus standard of care.